Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing: 2017 Update

Publisher： John Wiley & Sons Inc

E-ISSN： 1532-6535|103|2|210-216

ISSN： 0009-9236

Source： CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol.103, Iss.2, 2018-02, pp. : 210-216

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Clinical Pharmacogenetics Implementation Consortium Guidelines for Dihydropyrimidine Dehydrogenase Genotype and Fluoropyrimidine Dosing

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 94, Iss. 6, 2013-12 ,pp. : 640-645

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium Guidelines for Thiopurine Methyltransferase Genotype and Thiopurine Dosing: 2013 Update

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 93, Iss. 4, 2013-04 ,pp. : 324-325

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for Rasburicase Therapy in the Context of G6PD Deficiency Genotype

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 2, 2014-08 ,pp. : 169-174

John Wiley & Sons Inc

Access to resources Recommend Favorite

Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for IFNL3 (IL28B) Genotype and PEG Interferon‐α–Based Regimens

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 95, Iss. 2, 2014-02 ,pp. : 141-146

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Clinical Pharmacogenetics Implementation Consortium Guideline for SLCO1B1 and Simvastatin‐Induced Myopathy: 2014 Update

By  

CLINICAL PHARMACOLOGY & THERAPEUTICS, Vol. 96, Iss. 4, 2014-10 ,pp. : 423-428

John Wiley & Sons Inc

Access to resources Recommend Favorite